Loading stock data…
Arrowhead Pharmaceuticals, Inc. (ARWR)
$79.42+0.53 (+0.67%)
Market OpenUpdated 2:07 PM EDT
Arrowhead Pharmaceuticals, Inc.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Arrowhead Pharmaceuticals, Inc. in the Healthcare sector is trading at $79.42 with a market capitalization of $10.0B. Wall Street consensus targets $89.08 (12 analysts), implying a +12.2% move over the next 12 months. The stock is currently near its 52-week high of $84.55, remaining 33.1% above its 200-day moving average. On fundamentals, Piotroski 5/9 shows mixed financial quality, Altman Z in the safe zone. The Whystock Score of 100/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +12.2% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $73.74M↓ | $264.03M↑ | $256.47M↑ | $27.77M↓ | $542.71M |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$141.26M↓ | $40.81M↓ | $44.11M↑ | -$165.55M↓ | $381.20M |
| Net Income | -$132.73M↓ | $30.81M↑ | -$23.75M↑ | -$175.24M↓ | $370.44M |
Peer Comparison
JNJUNHPFE
Fundamentals
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. Its pipeline includes Plozasiran to reduce production of apolipoprotein C-III in Phase 3 studies; Zodasiran to reduce production of ang...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$9.98B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.29
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-49.01%
Volume
Today's trading volume
724,428
Recent News
3 Under-the-Radar Biotech Takeover Targets for the Next Pharma Buying Spree
Big pharma is hunting again, and patent cliffs are forcing buyers to overpay or miss out. Three mid-cap biotechs have quietly positioned themselves as prime acquisition targets, but only one offers the rare combination of a depressed valuation and a commercial product already gaining ground.
IONS Stock Jumps 4% After-Hours — Goldman Sachs Lifts Price Target On Tryngolza Approval
Goldman Sachs upped its price target on Ionis to $75 and maintained a ‘Neutral’ rating on the shares.
Arrowhead Pharmaceuticals Lines Up SHASTA Readout as REDEMPLO Launch Gains Traction
Arrowhead Pharmaceuticals (NASDAQ:ARWR) executives outlined upcoming clinical catalysts, early commercial trends and pipeline priorities during a Jefferies fireside chat, with Chief Medical Officer James Hamilton emphasizing that the company remains focused exclusively on siRNA therapeutics through
Arrowhead Data On Plozasiran Expands Cardiometabolic Opportunity And Investor Focus
Arrowhead Pharmaceuticals presented new clinical data on plozasiran in patients with moderate to severe renal or hepatic impairment at a major scientific congress. The data focused on efficacy and safety outcomes in these higher risk groups. A separate case report highlighted long term triglyceride reduction with plozasiran use during pregnancy. For investors watching Arrowhead Pharmaceuticals (NasdaqGS:ARWR), these updates come with the stock at $74.95 and 1 year gains of 387.6%. The move...
Bernstein Lifts PT on Arrowhead Pharmaceuticals (ARWR) Following Biotech’s Solid Start to 2026
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) is one of the best medical stocks to invest in according to billionaires. Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) received a rating update from Bernstein on May 13. The firm lifted the price target on the stock to $46 from $35, maintaining a Market Perform rating on the shares and stating that biotech has had […]